300482 Stock Overview
An in vitro diagnostics company, engages in the research and development, production, and sale of point-of-care testing products, and rapid diagnosis and chronic disease management solutions in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Guangzhou Wondfo Biotech Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥24.75 |
| 52 Week High | CN¥32.64 |
| 52 Week Low | CN¥19.20 |
| Beta | 0.69 |
| 11 Month Change | -4.37% |
| 3 Month Change | 18.25% |
| 1 Year Change | -20.83% |
| 33 Year Change | -36.08% |
| 5 Year Change | -31.63% |
| Change since IPO | -17.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300482 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -1.7% | -0.9% | -0.6% |
| 1Y | -20.8% | -10.6% | 3.2% |
Return vs Industry: 300482 underperformed the CN Medical Equipment industry which returned -10.6% over the past year.
Return vs Market: 300482 underperformed the CN Market which returned 3.2% over the past year.
Price Volatility
| 300482 volatility | |
|---|---|
| 300482 Average Weekly Movement | 8.3% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300482 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300482's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 3,404 | Zhongxiong Peng | www.wondfo.com.cn |
Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, and sale of point-of-care testing products, and rapid diagnosis and chronic disease management solutions in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious, fertility, and sexually transmitted diseases, as well as immunofluorescence devices to detect cardiovascular diseases, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and other diseases. It also provides blood coagulation, optical coagulation, and dry chemistry analyzers, as well as automatic chemiluminescence immunoassay and molecular diagnostic analyzers.
Guangzhou Wondfo Biotech Co.,Ltd Fundamentals Summary
| 300482 fundamental statistics | |
|---|---|
| Market cap | CN¥11.83b |
| Earnings (TTM) | CN¥523.75m |
| Revenue (TTM) | CN¥2.94b |
22.6x
P/E Ratio4.0x
P/S RatioIs 300482 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300482 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.94b |
| Cost of Revenue | CN¥1.09b |
| Gross Profit | CN¥1.85b |
| Other Expenses | CN¥1.32b |
| Earnings | CN¥523.75m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.10 |
| Gross Margin | 62.84% |
| Net Profit Margin | 17.80% |
| Debt/Equity Ratio | 10.1% |
How did 300482 perform over the long term?
See historical performance and comparison